Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HIV Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks

NCT00705705
View directory record Official record
Conditions
HIV Infections
Interventions
Network leader training, Standard HIV risk-reduction counseling
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resilience-based Psychosocial Intervention Among Children Affected by HIV/AIDS

NCT04653441
View directory record Official record
Conditions
Emotional Adjustment, Aids/Hiv Problem
Interventions
Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
8 Years to 17 Years
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT02607956
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 22, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Mobile Gaming App to Improve Adherence to PrEP

NCT05762705
View directory record Official record
Conditions
Medication Adherence, HIV/AIDS
Interventions
Multilevel Gaming Adherence Intervention, Treatment as Usual +
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
15 Years to 34 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Jackson, Mississippi • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

NCT00006153
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 22, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

El Camino HIV Prevention and Care Study

NCT07834853
View directory record Official record
Conditions
HIV Infections
Interventions
Camino Intervention
Behavioral
Lead sponsor
American University
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Berkeley, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

NCT07665372
View directory record Official record
Conditions
HIV
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

A Comparison of 141W94 and Indinavir in HIV-Infected Patients

NCT00002202
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 9:03 AM EDT
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

NCT01959672
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
Procedure · Drug · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

NCT00002453
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

NCT04865341
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
IMB, Information-Only Control
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
17 Years to 24 Years · Male only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 9:03 AM EDT
Terminated Not applicable Interventional

Computer-Assisted Adherence Program for Patients Taking Anti-HIV Drugs

NCT00051766
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Computer-based Intervention
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00064142
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

NCT01695954
View directory record Official record
Conditions
Hyperlipidemia, HIV
Interventions
Pitavastatin, Darunavir, Ritonavir, Efavirenz
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Targeting Effective Analgesia in Clinics for HIV - Intervention

NCT02564341
View directory record Official record
Conditions
HIV Infection, Pain, Drug Dependence
Interventions
Collaboration with an IT enabled nurse care manager, Education and academic detailing, Facilitated access to a specialist in addictions
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

NCT04650269
View directory record Official record
Conditions
Harm Reduction, HIV Infections, Drug Use
Interventions
Biktarvy 50Mg-200Mg-25Mg Tablet, HIV care
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

NCT00991354
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-B, IL-12 DNA plasmids
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 22, 2026, 9:03 AM EDT
Not listed Phase 1 Interventional

A Randomized Trial to Prevent HIV Among Gay Couples

NCT03189394
View directory record Official record
Conditions
HIV Infections
Interventions
PRIDE, ePRIDE, Men's Health
Behavioral
Lead sponsor
San Francisco State University
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

NCT00757783
View directory record Official record
Conditions
HIV
Interventions
ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF], atazanavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
15
States / cities
Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 22, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Biological · Other
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 22, 2026, 9:03 AM EDT